HK1214812A1 - 新的羥基- -雜芳基菲啶及其作爲 抑制劑的用途 - Google Patents

新的羥基- -雜芳基菲啶及其作爲 抑制劑的用途

Info

Publication number
HK1214812A1
HK1214812A1 HK16100490.7A HK16100490A HK1214812A1 HK 1214812 A1 HK1214812 A1 HK 1214812A1 HK 16100490 A HK16100490 A HK 16100490A HK 1214812 A1 HK1214812 A1 HK 1214812A1
Authority
HK
Hong Kong
Prior art keywords
pde4
heteroarylphenanthridines
novel hydroxy
inhibitors
pde4 inhibitors
Prior art date
Application number
HK16100490.7A
Other languages
English (en)
Inventor
Schmidt Beate
Flockerzi Dieter
Hatzelmann Armin
Zitt Christof
Barsig Johannes
Marx Degenhard
Kley Hans-Peter
Kautz Ulrich
Original Assignee
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Gmbh filed Critical Takeda Gmbh
Publication of HK1214812A1 publication Critical patent/HK1214812A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/04Drugs for disorders of the urinary system for urolithiasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
HK16100490.7A 2004-03-03 2016-01-18 新的羥基- -雜芳基菲啶及其作爲 抑制劑的用途 HK1214812A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04004973 2004-03-03
EP04106359 2004-12-07

Publications (1)

Publication Number Publication Date
HK1214812A1 true HK1214812A1 (zh) 2016-08-05

Family

ID=34921303

Family Applications (4)

Application Number Title Priority Date Filing Date
HK15108262.7A HK1207635A1 (zh) 2004-03-03 2015-08-26 新的羥基- -雜芳基菲啶及其作為 抑制劑的用途
HK15109032.4A HK1208447A1 (zh) 2004-03-03 2015-09-16 新的羥基- -雜芳基菲啶及其作為 抑制劑的用途
HK15109596.2A HK1208865A1 (zh) 2004-03-03 2015-09-30 新的羥基- -雜芳基菲啶及其作為 抑制劑的用途
HK16100490.7A HK1214812A1 (zh) 2004-03-03 2016-01-18 新的羥基- -雜芳基菲啶及其作爲 抑制劑的用途

Family Applications Before (3)

Application Number Title Priority Date Filing Date
HK15108262.7A HK1207635A1 (zh) 2004-03-03 2015-08-26 新的羥基- -雜芳基菲啶及其作為 抑制劑的用途
HK15109032.4A HK1208447A1 (zh) 2004-03-03 2015-09-16 新的羥基- -雜芳基菲啶及其作為 抑制劑的用途
HK15109596.2A HK1208865A1 (zh) 2004-03-03 2015-09-30 新的羥基- -雜芳基菲啶及其作為 抑制劑的用途

Country Status (29)

Country Link
US (8) US8003798B2 (zh)
EP (2) EP1723135B1 (zh)
JP (2) JP4801039B2 (zh)
KR (2) KR101152488B1 (zh)
CN (6) CN104803973A (zh)
AR (1) AR049319A1 (zh)
AU (1) AU2005219576B2 (zh)
BR (1) BRPI0508321B1 (zh)
CA (1) CA2557752C (zh)
CO (1) CO5700749A2 (zh)
CY (2) CY1114319T1 (zh)
DK (2) DK1723135T5 (zh)
EA (2) EA017282B1 (zh)
ES (2) ES2427256T3 (zh)
HK (4) HK1207635A1 (zh)
HR (2) HRP20130828T1 (zh)
IL (2) IL177073A (zh)
ME (1) ME01955B (zh)
MX (2) MX341474B (zh)
NO (2) NO336538B1 (zh)
NZ (1) NZ549108A (zh)
PL (2) PL2589599T4 (zh)
PT (2) PT1723135E (zh)
RS (2) RS52916B (zh)
SG (1) SG182194A1 (zh)
SI (2) SI2589599T1 (zh)
TW (2) TWI372750B (zh)
WO (1) WO2005085225A1 (zh)
ZA (1) ZA200606176B (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE353217T1 (de) 2002-08-29 2007-02-15 Altana Pharma Ag 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
US7585872B2 (en) 2004-02-18 2009-09-08 Nycomed Gmbh Guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (PDE) 4 inhibitors
CN104803973A (zh) 2004-03-03 2015-07-29 塔科达有限责任公司 新的羟基-6-杂芳基菲啶及其作为pde4抑制剂的用途
US20080119505A1 (en) 2005-02-01 2008-05-22 Altana Pharma Ag Novel 6-Pyridylphenanthridines
EA200701815A1 (ru) * 2005-03-02 2008-02-28 Никомед Гмбх 6-гетероарил-1,2,3,4,4а,10в-гексагидрофенантридины в качестве pde-4 ингибиторов для лечения воспалительных заболеваний
PL1856093T3 (pl) 2005-03-02 2010-05-31 Takeda Gmbh Chlorowodorek (2R,4aR,10bR)-6-(2,6-dimetoksy-pirydyn-3-ylo)-9-etoksy-8-metoksy-1,2,3,4,4a,10b-heksahydrofenantrydyn-2-olu
NZ574710A (en) * 2006-09-07 2012-02-24 Nycomed Gmbh Combination treatment comprising the PDE4 inhibitor Compound A ((2R,4aR, 10bR)6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1 ,2,3,4,4a,10b-hexahydrophenanthridin-2-ol) for diabetes mellitus
JP5694765B2 (ja) * 2007-05-17 2015-04-01 コーテックス ファーマシューティカルズ, インコーポレイテッド グルタミン酸作動性シナプス反応を増強するための二置換アミド
WO2009025823A1 (en) * 2007-08-21 2009-02-26 Amgen Inc. Phosphodiesterase 10 inhibitors
WO2009109525A1 (en) * 2008-03-03 2009-09-11 Nycomed Gmbh Use of a specific pde4 inhibitor for the treatment and/or prophylaxis of non-alcoholic fatty liver disease
AR074318A1 (es) * 2008-11-14 2011-01-05 Nycomed Gmbh Derivados heterociclicos de pirazolona, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades de las vias respiratorias.
CA2936332A1 (en) * 2014-01-22 2015-07-30 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
CN103936661B (zh) * 2014-04-04 2016-08-24 常州大学 一种6-烷基菲啶衍生物的合成方法
JP2018521077A (ja) * 2015-07-29 2018-08-02 タケダ ゲー・エム・ベー・ハーTakeda GmbH 糖尿病性腎症を治療するためのpde4阻害剤
CA3034956A1 (en) 2016-08-26 2018-03-01 Takeda Gmbh Treatment of nonalcoholic fatty liver disease
CN110573148A (zh) 2017-03-16 2019-12-13 武田有限公司 特发性肺纤维化的治疗
US11292782B2 (en) 2018-11-30 2022-04-05 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
WO2020113094A1 (en) * 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
TWI753296B (zh) * 2019-08-30 2022-01-21 國立陽明交通大學 11-芳香基噌啉[2,3-f]菲啶鹽化合物及其製造方法
TWI785816B (zh) * 2019-08-30 2022-12-01 國立陽明交通大學 11-芳香基噌啉[2,3-f]菲啶鹽化合物及其製造方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027055D0 (en) * 1990-12-13 1991-02-06 Sandoz Ltd Organic compounds
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
SI0706513T1 (en) 1993-07-02 2002-10-31 Altana Pharma Ag Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
SI0882021T1 (en) 1996-01-31 2003-10-31 Altana Pharma Ag New phenanthridines
SI0889886T1 (en) 1996-03-26 2003-02-28 Altana Pharma Ag Novel phenanthridines substituted in the 6 position
US6127378A (en) 1996-03-26 2000-10-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenanthridines substituted in the 6 position
JPH1020274A (ja) * 1996-07-05 1998-01-23 Fujitsu Ltd 液晶表示駆動回路及び液晶表示装置
WO1998021208A1 (en) 1996-11-11 1998-05-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Benzonaphthyridines as bronchial therapeutics
SI0968211T1 (en) 1997-03-07 2004-02-29 Altana Pharma Ag Tetrazole derivatives
DK0988302T3 (da) 1997-06-03 2003-06-02 Altana Pharma Ag Benzonaphthyridiner
IL133825A (en) 1997-07-25 2005-12-18 Altana Pharma Ag Substituted 6-phenylphenanthridines, medicaments containing same and use thereof in the production of medicaments
WO1999005112A1 (en) 1997-07-25 1999-02-04 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituted 6-alkylphenanthridines
ES2217575T3 (es) 1997-07-25 2004-11-01 Altana Pharma Ag Nuevos derivados de tetrazol.
ID24942A (id) * 1997-11-04 2000-08-31 Pfizer Prod Inc Senyawa terapi aktif yang berdasarkan penggantian bioisoster katekol dengan indazole pada inhibitor pde4
JP2002513793A (ja) * 1998-05-05 2002-05-14 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング 新規n−オキシド
DE59909760D1 (de) 1998-08-31 2004-07-22 Altana Pharma Ag Benzonaphthyridin-n-oxide mit pde3 und pde4 inhibierender aktivität
BR0007527B1 (pt) 1999-01-15 2011-12-27 fenilfenantridinas com atividade inibitària de pde-iv, seu uso, bem como medicamento compreendendo as mesmas.
ATE315029T1 (de) * 1999-01-15 2006-02-15 Altana Pharma Ag 6-arylphenanthridine mit pde-iv hemmender wirkung
US6534519B1 (en) 1999-01-15 2003-03-18 Altana Pharma Ag Phenanthridine-N-oxides with PDE-IV inhibiting activity
CA2360386A1 (en) 1999-01-15 2000-07-20 Beate Gutterer Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity
PT1147087E (pt) 1999-01-15 2005-09-30 Altana Pharma Ag Feantridina-n-oxidos com actividade de inibicao de pde-iv
EA005856B1 (ru) * 1999-10-25 2005-06-30 Алтана Фарма Аг Тетрагидротиопиранфталазиноновые производные в качестве ингибиторов pde4
JP2003519686A (ja) 2000-01-11 2003-06-24 アルタナ ファルマ アクチエンゲゼルシャフト フェナントリジン−n−オキシド
US6924292B2 (en) 2000-03-23 2005-08-02 Takeda Chemical Industries, Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
PT1303506E (pt) * 2000-07-14 2005-06-30 Altana Pharma Ag 6-heteroarilfenantridinas
WO2002006238A1 (en) 2000-07-14 2002-01-24 Altana Pharma Ag Cycloalkyl - or cycloalkylmethyl-substituted 6-phenylphenanthridines
AU2001281965A1 (en) 2000-07-14 2002-01-30 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Novel 6-phenylphenanthridines
ATE287403T1 (de) 2001-02-21 2005-02-15 Byk Gulden Lomberg Chem Fab 6-phenylbenzonaphthyidine
EP1581533A2 (en) 2002-08-17 2005-10-05 ALTANA Pharma AG Novel benzonaphthyridines
US20060116518A1 (en) 2002-08-17 2006-06-01 Altana Pharma Ag Novel phenanthridines
ATE353217T1 (de) 2002-08-29 2007-02-15 Altana Pharma Ag 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
EP1539164B1 (en) 2002-08-29 2006-12-20 ALTANA Pharma AG 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
RU2247262C2 (ru) 2003-05-19 2005-02-27 Федеральное государственное унитарное предприятие Российский Федеральный Ядерный Центр-Всероссийский Научно-исследовательский институт технической физики им. акад. Е.И. Забабахина (РФЯЦ- ВНИИТФ) Плунжерный насос сверхвысокого давления
US7585872B2 (en) 2004-02-18 2009-09-08 Nycomed Gmbh Guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (PDE) 4 inhibitors
CN104803973A (zh) 2004-03-03 2015-07-29 塔科达有限责任公司 新的羟基-6-杂芳基菲啶及其作为pde4抑制剂的用途
AR049419A1 (es) 2004-03-03 2006-08-02 Altana Pharma Ag Hidroxi-6-fenilfenantridinas sustituidas con heterociclilo
AU2005220034A1 (en) 2004-03-09 2005-09-15 Nycomed Gmbh Novel isoamido-substituted hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors
WO2005085203A1 (en) 2004-03-10 2005-09-15 Altana Pharma Ag Novel difluoroethoxy-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
NZ549254A (en) 2004-03-10 2010-06-25 Nycomed Gmbh Amido-substituted hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors
WO2005087744A1 (en) 2004-03-10 2005-09-22 Altana Pharma Ag Novel thio-containing hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
PL1856093T3 (pl) 2005-03-02 2010-05-31 Takeda Gmbh Chlorowodorek (2R,4aR,10bR)-6-(2,6-dimetoksy-pirydyn-3-ylo)-9-etoksy-8-metoksy-1,2,3,4,4a,10b-heksahydrofenantrydyn-2-olu

Also Published As

Publication number Publication date
MX341474B (es) 2016-08-19
US20150119389A1 (en) 2015-04-30
KR101152488B1 (ko) 2012-07-02
CY1114319T1 (el) 2016-08-31
RS52916B (en) 2014-02-28
DK1723135T5 (da) 2013-09-16
RS53543B1 (en) 2015-02-27
JP2007526283A (ja) 2007-09-13
ME01955B (me) 2015-05-20
TW201124381A (en) 2011-07-16
ZA200606176B (en) 2008-03-26
EA201000494A1 (ru) 2010-08-30
EP2589599B1 (en) 2014-06-25
CO5700749A2 (es) 2006-11-30
IL177073A0 (en) 2006-12-10
US9387205B2 (en) 2016-07-12
PL2589599T4 (pl) 2015-06-30
PT2589599E (pt) 2014-09-02
IL221323A0 (en) 2012-09-24
IL177073A (en) 2013-04-30
US20130045974A1 (en) 2013-02-21
CN1922170A (zh) 2007-02-28
SI1723135T1 (sl) 2013-10-30
PL2589599T3 (pl) 2015-04-30
ES2505473T3 (es) 2014-10-10
US20140073636A1 (en) 2014-03-13
DK2589599T3 (da) 2014-10-06
US8318944B2 (en) 2012-11-27
JP2011074094A (ja) 2011-04-14
HRP20140892T1 (hr) 2014-11-07
HK1208865A1 (zh) 2016-03-18
CN102295634A (zh) 2011-12-28
KR20060135837A (ko) 2006-12-29
CN104817534A (zh) 2015-08-05
US9962377B2 (en) 2018-05-08
TWI404704B (zh) 2013-08-11
AU2005219576A1 (en) 2005-09-15
EA200601568A1 (ru) 2007-02-27
EP2589599A1 (en) 2013-05-08
DK1723135T3 (da) 2013-09-02
SI2589599T1 (sl) 2014-10-30
US20080167301A1 (en) 2008-07-10
AU2005219576B2 (en) 2011-06-30
US20110257169A1 (en) 2011-10-20
JP5193320B2 (ja) 2013-05-08
NO20064221L (no) 2006-09-19
JP4801039B2 (ja) 2011-10-26
MXPA06009695A (es) 2007-03-26
HRP20130828T1 (en) 2013-09-30
AR049319A1 (es) 2006-07-19
EA014155B1 (ru) 2010-10-29
TWI372750B (en) 2012-09-21
EP1723135B1 (en) 2013-06-19
US20150352096A1 (en) 2015-12-10
KR101152439B1 (ko) 2012-07-06
CN104803974A (zh) 2015-07-29
CA2557752A1 (en) 2005-09-15
SG182194A1 (en) 2012-07-30
ES2427256T3 (es) 2013-10-30
NO336538B1 (no) 2015-09-21
US8883818B2 (en) 2014-11-11
EP1723135A1 (en) 2006-11-22
US9149479B2 (en) 2015-10-06
NO20141541L (no) 2006-09-19
HK1207635A1 (zh) 2016-02-05
TW200540158A (en) 2005-12-16
CA2557752C (en) 2012-10-02
NZ549108A (en) 2010-06-25
CY1115536T1 (el) 2017-01-04
US20160279120A1 (en) 2016-09-29
PL1723135T3 (pl) 2013-11-29
BRPI0508321A (pt) 2007-07-24
HK1208447A1 (zh) 2016-03-04
US8455653B2 (en) 2013-06-04
NO338326B1 (no) 2016-08-08
KR20120006080A (ko) 2012-01-17
WO2005085225A1 (en) 2005-09-15
EA017282B1 (ru) 2012-11-30
US8003798B2 (en) 2011-08-23
CN104761545A (zh) 2015-07-08
US20110257221A1 (en) 2011-10-20
US8324391B2 (en) 2012-12-04
CN104803973A (zh) 2015-07-29
BRPI0508321B1 (pt) 2018-02-06
PT1723135E (pt) 2013-08-29

Similar Documents

Publication Publication Date Title
HK1214812A1 (zh) 新的羥基- -雜芳基菲啶及其作爲 抑制劑的用途
EP1802588A4 (en) SUBSTITUTED AMINOPYRIMIDONE AND APPLICATIONS THEREOF
IL181670A0 (en) Substituted phenylaminothiazoles and use thereof
IL183180A0 (en) 1-alkynyl-2-aryloxyalkylamides and their use as fungicides
IL179497A0 (en) Carboranylporphyrins and uses thereof
IL189252A0 (en) Dihydroxyanthraquinones and their use
PL2215908T3 (pl) 2-alkilo-cykloalk(en)ylo-karboksamidy i ich zastosowanie jako fungicydów
IL180365A0 (en) Carboranylporphyrins and uses thereof
IL179791A0 (en) Pyridinylisoxazoles and their use as herbicides
GB0427723D0 (en) Compounds and their use
ZA200606669B (en) Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors
GB0405306D0 (en) Compounds and their use
GB0403617D0 (en) Compounds and their use
GB0410830D0 (en) Compounds and their use
GB0410831D0 (en) Compounds and their use
GB0410832D0 (en) Compounds and their use
GB0410833D0 (en) Compounds and their use
GB0411071D0 (en) Compounds and their use
GB0416630D0 (en) Compounds and their use
GB0423234D0 (en) Compounds and their use
GB0409379D0 (en) Compounds and their use
GB0407628D0 (en) Compounds and their use
GB0401243D0 (en) Compounds and their use
GB0409378D0 (en) Compounds and their use
GB0409377D0 (en) Compounds and their use